Correction: KML001 induces apoptosis and autophagic cell death in prostate cancer cells via oxidative stress pathway (PLoS ONE (2019)10:9 (e0137589)Doi: 10.1371/journal.pone.0137589);KML001 induces apoptosis and autophagic cell death in prostate cancer cells via oxidative stress pathway

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  You, Dalsan ^a   Kim, Yunlim ^a   Jang, Myoung Jin ^a   Lee, Chunwoo ^a   Jeong, In Gab ^a   Cho, Yong Mee ^a   Hwang, Jung Jin ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARSENIC DERIVATIVE; KML001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIOXIDANT; ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; SODIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOSE RESPONSE; DU145 CELL LINE; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PC3 CELL LINE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN CLEAVAGE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; ARSENITES; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SODIUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84944790480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0225087     Document Type: Erratum

References (31)

1. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315-3324. PMID: 10552940
2. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19(18):3852-3860. PMID: 11559723
3. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62(14):3893-3903. PMID: 12124315
4. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339(19):1341-1348. PMID: 9801394
5. Dilda PJ, Hogg P.J. (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33(6):542-564. PMID: 17624680
6. Aronson SM (1994) Arsenic and old myths. R I Med 77(7):233-234. PMID: 7919541
7. Glienke W, Chow KU, Bauer N, Bergmann L. (2006) Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 47(8):1629-1638. PMID: 16966277
8. Poonepalli A, Balakrishnan L, Khaw AK, Low GK, Jayapal M, Bhattacharjee RN, et al. (2005) Lack of poly(ADP-ribose) polymerase-1 gene product enhances cellular sensitivity to arsenite. Cancer Res 65(23):10977-10983. PMID: 16322246
9. Wei YM, Ou YX, Bai H, Lu JH, Zheng R.L. (2001) Down-regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines. Acta Pharmacol Sin 22(8):725-730. PMID: 11749846
10. Zhang Y, Cao EH, Qin J.F. (2005) Up-regulation oftelomere-bindingTRF1,TRF2 related to reactive oxygen species induced byAs(2)O(3) in MGC-803 cells. Eur J Pharmacol 516(1):1-9. PMID: 15904916
11. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. (2003) Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 63(9):2103-2108. PMID: 12727826
12. Qian W, Liu J, Jin J, Ni W, Xu W. (2007) Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk Res 31(3):329-339. PMID: 16882451
13. Phatak P, Dai F, Butler M, Nandakumar MP, Gutierrez PL, Edelman MJ, et al. (2008) KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Clin Cancer Res 14(14):4593-4602. doi: 10.1158/1078-0432.CCR-07-4572 PMID: 18628474
14. Zhang B, Suer S, Livak F, Adediran S, Vemula A, Khan MA, et al. (2012) Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol 82(2):310-321. doi: 10.1124/mol.111.076752 PMID: 22584221
15. Kim Y, Jeong IG, You D, Song SH, Suh N, Jang SW, et al. (2014) Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells. Anticancer Drugs 25(1):53-62. doi: 10.1097/CAD.0000000000000013 PMID:24100277
16. Kim Y, Kim YS, Kim DE, Lee JS, Song JH, Kim HG, et al. (2013) BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production. Autophagy; 9(12):2126-2139. doi: 10.4161/auto.26308 PMID: 24322755
17. Euhus DM, Hudd C, LaRegina MC, Johnson F.E. (1986) Tumor measurement in the nude mouse. J Surg Oncol 31(4):229-234. PMID: 3724177
18. You D, Jang MJ, Lee J, Jeong IG, Kim HS, Moon KH, et a.l. (2013) Periprostatic implantation of human bone marrow-derived mesenchymal stem cells potentiates recovery of erectile function by intracavernosal injection in a rat model of cavernous nerve injury. Urology 81(1):104-110. doi: 10.1016/j.urology.2012.08.046 PMID: 23122545
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M.J. (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249. doi: 10.3322/caac.20006 PMID: 19474385
20. So A, Gleave M, Hurtado-Col A, Nelson C. (2005) Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23(1):1-9. PMID: 15770516
21. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. (2004) Docetaxeland estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513-1520. PMID: 15470214
22. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502-1512. PMID: 15470213
23. Murgo AJ (2001) Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 6 Suppl 2:22-28. PMID: 11331437
24. Rosenblatt AE, Burnstein KL (2009) Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol 23(3):412-421. doi: 10.1210/me.2008-0235 PMID: 19131511
25. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. (2014) Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 15(2):81-94. doi: 10.1038/nrm3735 PMID: 24401948
26. Shen S, Kepp O, Kroemer G. (2012) The end of autophagic cell death? Autophagy 8(1):1-3. doi:10.4161/auto.8.1.16618 PMID: 22082964
27. Fruehauf JP, Meyskens FL Jr (2007) Reactive oxygen species: a breath of life or death? Clin Cancer Res 13(3):789-794. PMID: 17289868
28. Sauer H, Wartenberg M. (2005) Reactive oxygen species as signaling molecules in cardiovascular differentiation of embryonic stem cells and tumor-induced angiogenesis. Antioxid Redox Signal 7(11-12):1423-1434. PMID: 16356105
29. Simon HU, Haj-Yehia A, Levi-Schaffer F (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5(5):415-418. PMID: 11256882
30. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89(9):3354-3360. PMID: 9129042
31. Alemany M, Levin J. (2000) The effects of arsenic trioxide (As2O3)on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. Leuk Lymphoma 38(1-2):153-163. PMID: 10811458